Daniela Mihic-Probst
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma
Dummer R, Guckenberger M, Najafi Y, von Moos R, Mihic-Probst D, Michielin O, Braun R, Lindenblatt N, Hunger R, Siano M, Arnold A. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2016; 146:w14279.
Feb 22, 2016The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma
Feb 22, 2016Swiss Med Wkly 2016; 146:w14279
Dummer Reinhard, Guckenberger Merlin, Najafi Yousef, von Moos Roger, Mihic-Probst Daniela, Michielin Oliver, Braun Ralph, Lindenblatt Nicole, Hunger Robert E, Siano Marco, Arnold Andreas
Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques
Schoenewolf N, von Moos R, Schraml P, Gillessen Sommer S, Ochsenbein A, Simcock M, Moch H, Mihic-Probst D, Dummer R, Swiss Group for Clinical Cancer Research (SAKK). Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. Case Rep Oncol 2012; 5:280-9.
Jun 5, 2012Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques
Jun 5, 2012Case Rep Oncol 2012; 5:280-9
Schoenewolf Nicola L, von Moos Roger, Schraml Peter, Gillessen Sommer Silke, Ochsenbein Adrian, Simcock Mathew, Moch Holger, Mihic-Probst Daniela, Dummer Reinhard, Swiss Group for Clinical Cancer Research (SAKK)
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
Schraml P, Moch H, Schläppi M, Seifert B, Michielin O, Dummer R, Ochsenbein A, Simcock M, Mihic-Probst D, von Teichman A, von Moos R. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncol Rep 2012
May 18, 2012Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
May 18, 2012Oncol Rep 2012
Schraml Peter, Moch Holger, Schläppi Marc, Seifert Bettina, Michielin Olivier, Dummer Reinhard, Ochsenbein Adrian, Simcock Mathew, Mihic-Probst Daniela, von Teichman Adriana, von Moos Roger
CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma
Mihic-Probst D, Zhao J, Saremaslani P, Baer A, Öhlschlegel C, Paredes B, Komminoth P, Heitz P. CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma. Anticancer Res 2004; 24:19-26.
Feb 7, 2004CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma
Feb 7, 2004Anticancer Res 2004; 24:19-26
Mihic-Probst Daniela, Zhao Jianming, Saremaslani Parvin, Baer Angela, Öhlschlegel Christian, Paredes Bruno, Komminoth Paul, Heitz Philipp U